Values First Advisors Inc. bought a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,546 shares of the company’s stock, valued at approximately $30,000.
A number of other institutional investors have also recently made changes to their positions in SNDX. Vanguard Group Inc. lifted its holdings in shares of Syndax Pharmaceuticals by 19.9% during the 4th quarter. Vanguard Group Inc. now owns 4,335,353 shares of the company’s stock worth $93,687,000 after acquiring an additional 718,051 shares during the last quarter. Diversified Trust Co bought a new stake in Syndax Pharmaceuticals during the first quarter worth about $369,000. Nvwm LLC purchased a new position in shares of Syndax Pharmaceuticals in the 1st quarter worth about $1,022,000. Swiss National Bank increased its position in shares of Syndax Pharmaceuticals by 5.8% during the 1st quarter. Swiss National Bank now owns 150,600 shares of the company’s stock valued at $3,584,000 after purchasing an additional 8,200 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of Syndax Pharmaceuticals during the 1st quarter valued at about $2,614,000.
Syndax Pharmaceuticals Stock Down 1.3 %
NASDAQ:SNDX opened at $18.75 on Friday. Syndax Pharmaceuticals, Inc. has a twelve month low of $11.96 and a twelve month high of $25.34. The stock has a market cap of $1.59 billion, a P/E ratio of -5.82 and a beta of 0.91. The firm’s fifty day simple moving average is $19.25 and its 200 day simple moving average is $20.45.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on SNDX shares. Stifel Nicolaus upped their target price on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. JPMorgan Chase & Co. cut their price objective on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Bank of America lifted their target price on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Jefferies Financial Group began coverage on shares of Syndax Pharmaceuticals in a research note on Friday, June 28th. They issued a “buy” rating and a $37.00 price target for the company. Finally, Barclays raised their price objective on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $35.90.
Read Our Latest Analysis on Syndax Pharmaceuticals
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
Further Reading
- Five stocks we like better than Syndax Pharmaceuticals
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Texas Roadhouse Stock Steering for New Highs This Year
- Stock Average Calculator
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What is a Low P/E Ratio and What Does it Tell Investors?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report).
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.